WeedLife News Network

A post on Facebook, shared hundreds of times, claims that a “60 gram supply of Cannabis Oil” is “enough to treat one cancer patient”. It also includes an image of several plastic syringes which it claims contain cannabis oil, with the caption “Cancer Cure”.

While there is evidence some cannabis products can be beneficial to cancer patients, and research on this is ongoing, there is no current proof that cannabis oil can cure cancer. 

Claims that cannabis products can cure cancer are ‘misleading’

The Facebook post doesn’t provide any source for its claim that 60g of cannabis oil would be enough to treat one cancer patient, nor does it include any specific information about what types or stages of cancer could allegedly be treated with cannabis oil. 

The acquisition was announced in March this year, and APIRx stakeholders received almost 218.17 million new Incannex shares at a notional value of $0.573 each. The new shares are subject to a 12-month escrow for the vendors.

As part of the deal, APIRx founders Dr George Anastassov and Lekhram Changoer have joined Incannex as non-executive director and chief technical officer, respectively.

Commenting on the acquisition, Incannex chief executive officer and managing director Joel Latham said it follows a long relationship with Dr Anastassov and Mr Changoer that began in 2018.

“After extensive due diligence and corporate strategy assessments of the APIRx assets, we are excited and ready to commence development activities over our newly acquired portfolio of drug candidates.”

World’s largest medicinal cannabis drug portfolio

The Township of Ocean’s governing body is further weeding through the details in making changes to its cannabis business ordinance.

The first reading of the proposed amendments and supplements to the ordinance passed unanimously at this month’s committee meeting. Residents will have the opportunity to discuss the changes at the second reading of the ordinance at the August 2 Township Committee meeting.

“The Township of Ocean is now putting in place the criteria for cannabis in the Township of Ocean,” said Mayor Ben LoParo, adding that the governing body will review it before the vote in a public meeting. “The applicant will need to provide the ownership of the business, business plan, and community benefits.” The proposed ordinance requires applicants to pay a $2,500 non-refundable application fee. Additionally, the Township of Ocean plans to collect a $10,000 annual fee for businesses that operate cultivation, manufacturing or medical cannabis facilities in the municipality.

Four types of licenses will be available withing the municipality if the ordinance is approved. A Class 1 License is for Cannabis Cultivation; Class 2, Cannabis Manufacturing, Class 3, Cannabis Wholesale; and Class 4, Cannabis Distribution. A separate license covers medical dispensaries. LoParo pointed out that the ordinance excludes the retail sale of recreational marijuana even though 57 percent of the municipality’s voters were in favor of the legalization of adult recreational cannabis use.

“I don’t think that’s right,” said LoParo. “I think we should include it because our voters said yes. We’re doing our people a disservice by not giving them what they voted for…We’re also giving up two percent of the recreational income, which could wind up to be hundreds of thousands of dollars in our tax account.”

LoParo pressed for feedback from the two other members of the township committee. Deputy Mayor Ken Baulderstone said he first wanted to see how the medical dispensary “worked out” before considering recreational retail sales. “The steps that we have taken are already more than eighty percent of the municipalities in the state,” Baulderstone stated.

The use of medical cannabis is rapidly rising in the United States. Of the 50 states, 37 have legalized medical marijuana and 19 have legalized recreational use. This has resulted in a total of $3.7 billion in cannabis tax revenue and increasingly widespread awareness of the plant’s pain-relieving qualities and potential to treat other illnesses and conditions.

According to a study published in Annals of Internal Medicine, the number of registered U.S. medical cannabis patients quadrupled between 2016 and 2020 to nearly 3 million total. This supports statistics from cannabis health technology company Veriheal, which reported 170,000 newly enrolled Florida patients in 2020 alone.

Medicinal Marijuana as an Alternative to Pills

The cannabis plant can assist in alleviating various conditions, from insomnia and Crohn’s disease to PTSD and depression. Considering that over 20% of Americans suffer from chronic pain—historically the most common reason people opt for medical cannabis—researchers have homed in on the potential of cannabis as a safer alternative to addictive opioid-based painkilling medications. Opioids have claimed hundreds of thousands of U.S. lives since the 1990s.

A study published in 2015 found that the use of medical cannabis “was associated with improvements in pain, function, quality of life and cognitive function.” The efficacy of cannabis as pain treatment has led to significant decreases in opioid use. According to a study, opioid overdose deaths were reduced by 25% in states that enacted medical cannabis programs.

Millennials were the biggest demographic of medical marijuana cardholders in 2020, followed by Generations X and Z. Statistics indicate that the COVID-19 pandemic combined with heavy political tension in 2020 caused these groups to experience depressive episodes, stress, and anxiety. Instead of seeking out traditional medications that often come with severe side effects, these groups chose cannabis as a tool for improving their mental health.

Is there a relationship between cannabis use and outcomes in spinal surgery and other procedures?

While there is limited literature examining the potential connection, a team of orthopedic specialists sought further answers. They ultimately found that patients with a history of cannabis use are indeed less likely than non-users to experience adverse medical outcomes after thoracolumbar (lower back) spinal fusion (TLF) surgery. The study, “The Impact of Isolated Baseline Cannabis Use on Outcomes Following Thoracolumbar Spinal Fusion: A Propensity Score-Matched Analysis” was recently published in The Iowa Orthopedic Journal.

The orthopedic specialists, affiliated with the State University of New York (SUNY) Downstate Health Sciences University in Brooklyn, analyzed the relationship between cannabis use and surgical outcomes with a 704-patient cohort, all undergoing TLF surgery for adult spinal deformity (ASD). Researchers queried the New York Statewide Planning and Research Cooperative System database between January 2009 and September 2013 to identify all patients who underwent TLF for ASD. To be included, individuals were over the age of 18 and had either minimum 90-day or two-year follow-up surveillance.

According to the researchers, ASD is a spectrum of disorders presenting in late adolescence or adulthood and includes adult spinal scoliosis, iatrogenic spinal deformity and primary degenerative sagittal imbalance. The authors note that, as life expectancies increase, the prevalence of ASD is rising and more surgical corrections are expected to occur in the future.

“With shifting public sentiment, expanding decriminalization, and a lack of objective data on the potential consequences of cannabis use, it is imperative to identify how baseline cannabis use impacts postoperative outcomes of patients with adult spinal deformity (ASD) undergoing thoracolumbar fusion (TLF),” the study reads.

Half of the sample identified themselves as cannabis consumers and the other half did not. The study looked to compare 90-day complication, 90-day readmission, and two-year revision rates between cannabis users and non-users.

Though marijuana use is now legal in most of the United States, questions remain about how smoking marijuana can affect lung health and the risk of lung cancer in particular.

Research has suggested that smoking marijuana can cause damage to the lungs but is not as detrimental as smoking tobacco.2-4 Studies have also indicated that smoking marijuana may not increase a person’s risk of lung cancer, but robust evidence is lacking.2-9

“We concluded that there is moderate evidence that there is no association between cannabis smoking and lung cancer,” said Donald I. Abrams, MD, professor emeritus of medicine at the University of California San Francisco and integrative oncologist at the USCF Osher Center for Integrative Health. 

Dr Abrams is one of the experts who reviewed evidence on the health effects of cannabis for a report published in 2017 by the National Academies of Sciences, Engineering, and Medicine (NASEM).

Among the research reviewed for that report was a pooled analysis of 6 case-control studies encompassing 2159 individuals with lung cancer and 2985 control participants. The analysis showed “little or no association” between the intensity, duration, cumulative consumption, or age at the start of cannabis smoking and the risk of lung cancer. 

Another study reviewed for the NASEM report was a population-based study of cannabis use in 49,321 Swedish military conscripts. Researchers evaluated the risk of lung cancer over a 40-year follow-up period. They found a 2-fold increase in lung cancer risk among participants with a history of “heavy” cannabis use (defined as having smoked more than 50 times at baseline) compared with those who had no history of cannabis use. 

A new study shows further evidence of the harms of vaping.

Conducted by researchers from Portland State University and published in the journal of Chemical Research in Toxicology, the study claims that the process of heating up cannabinoid acetates creates a toxic gas called ketene that’s harmful to the lungs.

Researchers tested different cannabinoid acetates and tried to measure how much ketene was produced in a single vape puff. They measured acetates like delta-8 THC, a compound that’s currently unregulated by the FDA and that’s potent, crossing the blood-brain barrier more easily.

Researchers found that ketene is formed at lower settings of heat than anticipated and that each puff releases an amount of toxin that’s dangerous to people’s health. Ketene is supposedly so toxic to humans that it’s dangerous to even test it, thus, becoming difficult to measure its impact on the human body.

“The thing we’re most concerned about is prolonged exposure, we don’t know what that is,” said Kaelas Munger, a doctoral student and one of the authors of the study.

“That’s why papers like ours are needed. Otherwise people would be exposed to this really toxic substance and it’s really impossible to look for the evidence.”

MedPharm Research, a leading cannabis researcher, announced today that the company’s proposal, which was submitted to the FY23 Cannabis Research Opportunity at the Colorado State University Institute of Cannabis Research (ICR), titled “Isolation and Pharmacological Evaluation of Phytocannabinoids for Alzheimer’s Disease,” has been selected for funding.

Scoring of the proposal was organized into six categories: significance, approach, broader impacts, environment, data analysis, and environment. Reviewers from the ICR review panel applauded the novelty of the project, the training needed for a scientific intern, and how well the proposal defines the metric of evaluation for each data analysis aim. They concluded that the likelihood of the project to succeed is high, adding that minor cannabinoids is an area where more research is needed.

According to the Center for Disease Control, Alzheimer’s disease and related dementias are projected to grow to 13.9 million, nearly 3.3 percent of the population in 2060. Brains of people with Alzheimer’s show neurodegeneration and high levels of oxidative stress and inflammation.

“The study results will allow MedPharm to further develop innovative, bioavailable, and bioequivalent dosage forms. These are important elements in support of Investigational New Drugs (INDs) and New Drug Applications (NDAs) for future FDA-approved products,” says Scott Karolchyk, MS, RPh, Director of Formulation and Development. The phytocannabinoid cannabidiol (CBD) has neuroprotective, antioxidant and anti-inflammatory properties. Other studies have shown that CBD has been shown to be effective in vivo, making the phytocannabinoid an interesting candidate for novel therapeutic interventions in Alzheimer’s therapy, especially because there are no psychoactive or cognition-impairing properties, thus adding to the significance of the MedPharm study.

“It’s by pursuing this one-of-a-kind study in an area where research is really needed that sets MedPharm apart from other cannabis research and development companies,” Albert Gutierrez, President of MedPharm, says.

WEED, Inc. a global cannabis & hemp bioresearch company based in the USA, focused on the development and application of cannabis-derived compounds for the treatment of human and animal diseases, acquired 100% of Hempirical Genetics, LLC, for 2 million shares of common stock valued at $.25 per share and $250,000 in cash over 4 years. One million shares and $10,000 was paid on signing this agreement. (Benzinga)

Glenn E. Martin, WEED, Inc.'s CEO stated, "Our teams in USA, Australia and Israel are excited that a pipeline of Original "Landrace" strains from the 1970s' can now be moved into clinical trials and product development for the global market. WEED now has over 15 "PURE" original, pristine, F-1 grade cannabis strains today, including, Panama Red, Acapulco Gold, Red Bud Colombian & Santa Marta Gold. Our newly acquired inventory includes over 30 CBD & CBG strains as WEED believes that multiple combinations of precise cannabinoid strains will create the entourage effect to achieve the medical outcome desired. Eventually, WEED plans to bring our unique desired strains to the Adult Use markets once the "Law of the Land" brings back the Freedoms lost 70+ years ago."

Miller stated, "I've known Glenn Martin for 50+ years and honored to take the helm of HEMP BioSciences to buildout our genetic studies. My goal is to bring the strongest, highest quality THC and hemp products to market at affordable prices.

"Double the quality, half the price" should be the mantra for the cannabis industry, while creating diversity & equality to the cannabis sector. Our Veterans have been highly overlooked, and I look to develop vet programs at low or no cost, which I know is a priority of Glenn and mine."

The Cannabis Scientist Power List is an annual recognition of the most important innovators within the cannabis industry

WeCare-MedicalCannabis’ A Comprehensive Resource for Medical Cannabis Education is Now Available in English, German, French, and Portuguese

 Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today announced that its medical cannabis division, Tilray Medical, launched a new cannabis education platform, WeCare-MedicalCannabis, dedicated to providing resources and educating healthcare practitioners and patients about medical cannabis.

WeCare-MedicalCannabis provides science and research-based cannabis content tailored to healthcare professionals, caregivers, and patients to help them make informed decisions about medicinal cannabis and assists them along their path to discovering how medicinal cannabis can support daily wellness and health. Designed to serve as a one-stop, comprehensive resource on medical cannabis insights, WeCare-MedicalCannabis is now available in Germany, France, the United Kingdom, and Portugal.

Sascha Mielcarek, Managing Director, Tilray Europe, said, “As global pioneers in medical cannabis, we are aware of the lack of access to science-based, medical cannabis education. WeCare-MedicalCannabis was created to bridge that gap and help provide the needed resources to helping patients, caregivers, and healthcare professionals with the information they need to make informed decisions on medicinal cannabis. As cannabis legalization continues to expand across Europe, Tilray Medical is dedicated to help provide informed and trusted guidance for those interested in learning more about medical cannabis.”

Tilray Medical continues to work with leading patient associations and physician societies, providing value to those impacted by changes within the medical landscape, and who serve at the forefront of global health initiatives. By providing access to educational platforms such as WeCare-MedicalCannabis, Tilray Medical continues to open and expand its world of wellbeing.

No, you can’t make up for your bad eating habits just by working out. Here’s what a new study says will actually work.

New research highlights a sad reality — no matter how much you work out or how healthy you eat, a longer life will only occur if you do both of these things together.

The large study was published in the British Journal of Sports Medicine and counters the popular belief that working out eliminates some of the risks of eating an unhealthy diet or that eating healthy things counteracts staying in bed all day.

Researchers had a lot of data at their disposal, allowing them to publish a study that was thorough and that shed some light on a lot of issues. The data belonged to UK Biobank and came from over 350,000 people with a median age of 57, who filled out questionnaires about their diets and habits. At the start of the study, participants were healthy.

The study made some expected discoveries, like learning that participants who eat healthily and work out often had a lower mortality risk. Still, results highlighted that a healthy diet and frequent exercise were important independently.

“Physical activity is important. And whatever your physical activity is, diet is important,” said Dr. Melody Ding, lead author of the study.

The new phase 2b trial expands on successful phase 2a findings, in which treatment with SCI-110 resulted in a 21% reduction in tics across a cohort of adults with Tourette syndrome.

SciSparc, a pharmaceutical company in development of central nervous system therapies, has begun the process of submitting an investigational new drug application (IND) for a phase 2b trial to evaluate their cannabis-derived agent SCI-110 in patients with Tourette Syndrome (TS). As part of the submission, the company is looking to expand the trial and include a site in the US.

The newly announced phase 2b trial stems from results of a previously conducted phase 2a trial, which showed that treatment using SCI-110 led to a 21% reduction of tic symptoms across a sample of patients with medically refractory TS. Additionally, the agent was proven to be safe, with no concerning AEs, and improved patients’ tic symptoms over time on the Yale Global Tic Severity Scale.

The news stems weeks after the company announced that it successfully completed the development of the formulation to be used in the multinational phase 2b study,2 along with news from January 2022 that they entered agreements to test the drug at 2 clinical trial sites in Hannover, Germany, and Tel-Aviv, Israel.3 SCI-110, currently in development for other indications, such as obstructive sleep apnea and Alzheimer disease (AD) agitation, contains a combination of dronabinol, an FDA-approved synthetic form of tetrahydrocannabinol (THC), with endocannabinoid palmitoylethanolamide (PEA).

The new multinational, double-blind, placebo-controlled crossover trial will evaluate the safety, efficacy, and tolerability of the agent in a cohort of adults aged 18 to 65 years with TS. Patients will be randomly assigned 1:1 to either study drug or placebo and evaluated on tic severity change at end points of week 12 and week 26 using commonly frequented measures. Additionally, the primary safety objective of the trial will be to assess absolute and relative frequencies of serious adverse events (AEs) for the entire population and separately for the SCI-110 and placebo groups.

"We are very excited about expanding our clinical sites to the US, especially after positive results obtained in a clinical trial led by professor Bloch MD, MS, an associate Professor in the Child Trial Center at Yale University, using our proprietary drug candidate," Adi Zuloff-Shani, chief technologies officer, SciSparc, said in a statement.

Further testing on pesticides used to cultivate marijuana is one way to ensure all the consumers are safe from harmful chemicals.

As Rhode Island gears up for its recreational sales debut this December, it now requires all of its cannabis pass pesticide testing. This process is common, as nearly all legal states have some form of pesticide testing in place. With cannabis being illegal on a federal level, however, one is left to question exactly how rigorous this testing is.

In fact, since marijuana is not technically a food product or controlled at all by any federal body, one has to wonder exactly what type of pesticides we might be consuming with our recreational, and even medical marijuana. The answer, just like with marijuana policy in general, is that it varies significantly from state to state.

Arizona is a good example of how some states are handling pesticide oversight. The state of Arizona determined that testing for pesticides in marijuana was essential before it is placed on shelves, “but unlike other states, regulators here don’t do their own testing to ensure they are safe,” wrote AZ Central. The state has a third party test its marijuana, which puts full faith in this outside company to provide accurate and reliable information. This is not an uncommon practice since marijuana policy is still enjoying its “Wild West” phase in many newly-legal states.

The fact is, pesticide testing varies significantly from state to state. In a2021 study, “six states imposed the strictest U.S. EPA tolerances (i.e. maximum residue levels) for food commodities on up to 400 pesticidal active ingredients in cannabis, while pesticide testing was optional in three states.” The study found that the action levels of regulated pesticides were very different depending on what jurisdiction it came from. 

The main reason for this inconsistency is due to the fact that the main agency that regulates and monitors pesticide use in the US is currently not at all involved in regulating marijuana pesticides. According to the EPA, they have not registered any pesticides for marijuana. This is because as a federal organization they cannot make policy for a substance that is deemed a Schedule 1 drug. Instead, the responsibility and authority is left to the states that have legalized marijuana.

CBD is a natural way to treat a range of health issues and can have a positive impact on our overall health and wellbeing. It can help with illness and injuries that cause pain and discomfort. It can also help with skin conditions like acne and eczema and can alleviate symptoms we may suffer caused by low mood and bad mental health. There is a product to suit everyone, from CBD softgels to oils, capsules, and gummies. Below, we’ll look at how adding CBD to your daily routine can help you overcome common health issues.

What is CBD?

CBD is extracted from the cannabis plant to make an all-natural substance, that is often used to boost health and well-being. Although it is produced within the cannabis plant, you won’t experience the common ‘high’ feeling associated with the drug, as this is produced by a separate chemical called THC – there should be no THC present in your CBD products. CBD can be mixed with other natural substances to make an oil to be taken orally, or you may also find it in the form of infused creams and lotions, capsules, gummies and even bath bombs – there is something to suit everyone!

How does it work?

CBD interacts with the endocannabinoid systems within our body. These symptoms are made up of receptors – CBD works with them and changes the way that they react to pain, and in turn, creates an anti-inflammatory effect, which is why CBD is commonly used to treat pain caused by chronic illness and injuries. It can also interact with the production of serotonin in our brain, which is the chemical that causes us to feel happy and can balance production to reduce feelings of stress, anxiety, and low mood.

Generally, CBD is used to balance various systems in the body, whether you’re experiencing pain, feeling down, or stressed, or something within your body is causing you to feel unlike yourself – taking CBD in one of its many forms can help.

What are the health benefits?

As previously mentioned, CBD products come with a variety of benefits, from relieving pain and discomfort to alleviating physical and mental symptoms of stress and anxiety. Below, we’ll look at these benefits in more detail and how CBD can promote good health.

A study funded by Quantified Citizen, co-authored by Paul Stamets, proves that psilocybin treatment can help boost mood and mental health.

A study published in Scientific Reports on June 30 has presented evidence that psilocybin mushrooms have a noticeable effect on the mood and mental health of participants.

The study, called “Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls,” analyzed 1,133 subjects between November 2019 to May 2021. Baseline assessment was conducted at the beginning of the study, and then again between 22-35 days later.

Researchers analyzed the results of psilocybin microdosing combined with either lion’s mane mushrooms (Hericium erinaceus, or abbreviated as HE) or niacin (vitamin-B3) to identify “small- to medium-sized improvements in mood and mental health that were generally consistent across gender, age and presence of mental health concerns … improvements in psychomotor performance that were specific to older adults.” The study refers to these combinations as “stacking.”

The study abstract notes that combining psilocybin with HE or B3 “did not impact changes in mood and mental health,” however, older participants did experience psychomotor improvements through either just psilocybin, or psilocybin and HE.

The research was written by numerous authors including Paul Stamets, as well as Joseph M. Rootman of University of British Columbia’s Department of Psychology. According to an interview with Forbes, Rootman is certain that the work being conducted now will help lead to more revelations in the future. “This study is an extension of our earlier manuscript published in the same journal, and we have further publications in preparation that are based on this same study,” said Rootman. “Our team has also been working hard to develop the next version of the study which will be used to generate findings related to psychedelic microdosing for years to come.”

Adolescents are over three times more vulnerable to developing a cannabis addiction than adults, but may not be at increased risk of other mental health problems related to the drug, finds a new study led by UCL and King’s College London researchers.

The study, published today in the Journal of Psychopharmacology, found that adolescents who used cannabis were no more likely to have higher levels of subclinical depression or anxiety than adults who use cannabis, nor were they more vulnerable than adult users to the associations with psychotic-like symptoms.

These findings build on a separate study by the same team, published recently in Psychopharmacology that found adolescents were not more vulnerable to associations between chronic cannabis use and cognitive impairment.

Lead author Dr Will Lawn (UCL Clinical Psychopharmacology Unit and Institute of Psychiatry, Psychology and Neuroscience at King’s College London) said:

“There is a lot of concern about how the developing teenage brain might be more vulnerable to the long-term effects of cannabis, but we did not find evidence to support this general claim.

“Cannabis addiction is a real issue that teenagers should be aware of, as they appear to be much more vulnerable to it than adults.

Cannabis use does not seem to be associated with more respiratory-related emergency department visits compared non-users of the drug

Cannabis use is not associated with more respiratory-related visits to an emergency department in comparison to those who do not use the drug although it is associated with a greater proportion of overall emergency department visits. This was the main conclusion of a propensity-matched study by a group of researchers from Ontario, Canada.

Cannabis (or marijuana) is the most commonly used addictive drug after tobacco and alcohol. The use of cannabis is associated with respiratory problems such as chronic bronchitis symptoms and large airway inflammation and in fact, heavy use may lead to airflow obstruction. Despite this evidence of adverse respiratory effects, a 2018 systematic review concluded that there was low-strength evidence that smoking cannabis was associated with cough, sputum production, and wheezing and that there was insufficient evidence of an association between use of the drug and obstructive lung disease. Nevertheless, one study has suggested that daily cannabis smoking, even in the absence of tobacco, is associated with an elevated risk of health care use for various health problems.

With some uncertainty over the respiratory effects of cannabis, in the present study, the Canadian team wanted to examine the magnitude of the association between the use of cannabis and adverse respiratory-related emergency department visits. They conducted a retrospective analysis linking health survey and health administrative data for residents of Ontario. Individuals who self-reported any use of cannabis (the exposed group) within the past year were matched 1:3 (to increase the sample size) with control individuals, which were those who self-reported no use of the drug. The primary outcome for the study was a respiratory-related emergency department visit or hospitalisation which included both upper and lower respiratory tract infections, respiratory failure, asthma or COPD as the reason for presentation at the hospital. As a secondary outcome, the team assessed all-cause emergency department visits.

Cannabis use and respiratory-related hospital visits

A total of 35,114 individuals were included in the analysis, of whom, 6,425 with a mean age of 32.2 years (38.8% female) were self-reported cannabis users. Overall, 42.5% of those using the drug did so less than once a month with a much smaller proportion (10.5%) reporting daily use.